Listing Of MNC Divisions In India Has Been Rough Ride With Stray Sparks Of Hope
This article was originally published in The Pink Sheet Daily
Executive Summary
Large pharmaceutical companies realize the importance of emerging markets, including India, and are now calling for easing of restrictions and a level playing field.
You may also be interested in...
Are Emerging Markets Part Of Big Pharma's Core Business?
As Big Pharma companies increasingly look to emerging markets to capture some of the growth lost from the patent cliff in the U.S. and Europe, they are also shifting focus more to branded generics, leaving some investors to question whether companies would be better off spinning out their emerging market units, which would leave behind smaller companies focused on the core business of developing and marketing innovative therapies
Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent
MUMBAI - After Novartis and Mylan, it's now Pfizer's turn to increase its equity holding in its Indian operations. In an announcement to the Bombay Stock Exchange, Pfizer said it has decided to acquire an additional stake of 33.77 percent in Pfizer India through an open offer from public shareholders at a price of 675 rupees per share ($13.23)
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.